Does Medicare Advantage Cover Fosamax (Alendronate)?

How Medicare Advantage Prescription Drug Coverage Works for Alendronate

Medicare Advantage (Part C) plans that include Part D prescription drug coverage, sometimes called MA-PD plans, must cover at least two drugs in every therapeutic category and pharmacological class per CMS formulary requirements. Because alendronate is the most widely prescribed oral bisphosphonate for osteoporosis, it appears on nearly every MA-PD formulary in the United States.

Generic alendronate became available in 2008 after Merck's patent on Fosamax expired. This drove wholesale prices below $1 per tablet for the 70 mg weekly formulation. For Medicare Advantage enrollees, this means the drug almost always occupies Tier 1 (preferred generic), which carries the lowest cost-sharing bracket in a plan's benefit structure.

The CMS Part D benefit design includes four coverage phases: deductible, initial coverage, coverage gap (the so-called "donut hole"), and catastrophic coverage. Under the Inflation Reduction Act of 2022, the Part D out-of-pocket maximum is capped at $2,000 per year beginning in 2025. For a drug as inexpensive as generic alendronate, most beneficiaries will never approach that cap from this medication alone.

Plans differ by carrier. UnitedHealthcare, Humana, Aetna, Cigna, and Blue Cross Blue Shield each administer Medicare Advantage contracts in different regions with different formulary designs. Confirming your specific plan's formulary through the Medicare Plan Finder is the most reliable step before filling a prescription.

What Formulary Tier Is Alendronate on Medicare Advantage?

Generic alendronate sits on Tier 1 or Tier 2 in most Medicare Advantage Part D formularies, resulting in copays between $0 and $15 per 30-day supply. Brand-name Fosamax, if listed at all, typically falls on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), carrying copays of $30 to $95 per month.

CMS publishes annual formulary guidance requiring MA-PD plans to maintain broad coverage within each drug class. Oral bisphosphonates (alendronate, risedronate, ibandronate) represent a core pharmacological class for osteoporosis management, so plans cannot exclude them entirely.

Some plans offer $0 copays for Tier 1 generics as a competitive benefit. If your plan charges any copay for generic alendronate, compare against GoodRx or Mark Cuban's Cost Plus Drugs pricing. The cash price for generic alendronate 70 mg (4 tablets) averages $4 to $18, which may be cheaper than your plan copay in certain cases.

A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that formulary restrictions on osteoporosis medications were associated with lower treatment adherence and higher fracture rates. Patients who face formulary barriers should work with their prescribing clinician to request an exception or switch to a covered alternative.

Prior Authorization Requirements for Fosamax on Medicare Advantage

Prior authorization is rarely required for generic alendronate on Medicare Advantage plans. Most carriers classify it as an unrestricted Tier 1 generic, meaning the pharmacy can dispense it without additional plan approval the moment a valid prescription arrives.

Brand-name Fosamax is a different story. Because a therapeutically equivalent generic exists at a fraction of the cost, many MA-PD plans impose prior authorization or mandatory generic substitution for the brand product. If a prescriber writes "Fosamax" with "dispense as written" (DAW), the plan may require documentation that the patient cannot tolerate generic alendronate before covering the brand.

The 2020 Endocrine Society Clinical Practice Guideline on pharmacological management of osteoporosis recommends oral bisphosphonates, including alendronate, as first-line pharmacotherapy for postmenopausal women and older men at high fracture risk. This guideline status means plans have little clinical basis for restricting generic alendronate access.

Situations where prior authorization may apply, even for generic alendronate, include off-label uses, doses outside the FDA-approved range, or prescriptions exceeding plan quantity limits. The standard approved regimen is 70 mg once weekly or 10 mg once daily for osteoporosis treatment, and 35 mg once weekly or 5 mg once daily for prevention, per the FDA-approved prescribing information.

Does Medicare Advantage Require Step Therapy Before Fosamax?

No. Alendronate is itself the first-line step therapy agent for osteoporosis, so Medicare Advantage plans do not require patients to try a different drug before accessing it. Step therapy restrictions in osteoporosis pharmacotherapy typically apply to more expensive second-line agents like denosumab (Prolia) or teriparatide (Forteo), not to alendronate.

The rationale is straightforward. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=6,459), demonstrated that alendronate reduced the risk of clinical vertebral fractures by 55% (RR 0.45, 95% CI 0.27 to 0.72) and hip fractures by 51% (RR 0.49, 95% CI 0.23 to 0.99) over 4 years in women with low bone mineral density [1]. These results established alendronate as the reference standard oral bisphosphonate.

If your plan denies a more expensive osteoporosis drug like denosumab or romosozumab, the insurer will likely require documented failure of, intolerance to, or contraindication for an oral bisphosphonate (usually alendronate) first. This is the standard step therapy sequence across both Medicare Advantage and commercial plans. A prescriber who documents esophageal stricture, inability to remain upright for 30 minutes, or confirmed GI intolerance after an adequate alendronate trial (typically 3 to 6 months) satisfies most plans' step therapy criteria for advancing to injectable agents.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Oral bisphosphonates are recommended as initial pharmacologic therapy for most patients with osteoporosis." This consensus position reinforces why plans do not gate access to alendronate behind other drugs.

How to Appeal a Medicare Advantage Denial of Fosamax

If your Medicare Advantage plan denies coverage for alendronate or brand-name Fosamax, federal law guarantees a structured appeal process with multiple levels of review. Denials of generic alendronate are uncommon but can occur for dosing or quantity-limit reasons.

Level 1: Plan Redetermination. File a written appeal with your MA-PD plan within 60 days of the denial notice. The plan must respond within 7 calendar days for a standard request or 72 hours for an expedited request. Include the prescriber's letter of medical necessity, relevant lab results (DXA T-scores), and the specific CMS formulary exception you are requesting.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case automatically forwards to the IRE, currently administered by MAXIMUS Federal Services. MAXIMUS reviews the clinical evidence independently of the plan. According to CMS data on Part D appeals, IRE decisions overturn plan denials in a substantial percentage of cases when adequate clinical documentation accompanies the request.

Level 3 and beyond. Unsuccessful IRE appeals can proceed to an Administrative Law Judge (ALJ) hearing if the amount in controversy meets the annual threshold ($190 in 2025), then to the Medicare Appeals Council, and finally to federal district court.

For generic alendronate specifically, the most common denial scenario involves quantity limits rather than outright coverage refusal. If your prescriber orders the 10 mg daily formulation instead of the 70 mg weekly tablet, the plan may flag this as exceeding quantity limits. A simple switch to the weekly formulation typically resolves the issue without a formal appeal.

The prescriber can also file a formulary exception request. CMS requires MA-PD plans to grant exceptions when the prescriber demonstrates that the requested drug is medically necessary and that formulary alternatives would not be as effective or would cause adverse effects for the specific patient [2].

Cost Comparison: Generic Alendronate vs. Brand Fosamax on Medicare Advantage

Generic alendronate costs Medicare Advantage beneficiaries between $0 and $15 per month at most pharmacies, making it one of the least expensive osteoporosis treatments available. Brand-name Fosamax carries a manufacturer list price near $80 per month, though actual out-of-pocket costs depend on formulary tier and plan design.

Here is how costs typically break down across Medicare Advantage coverage phases for generic alendronate (70 mg, 4 tablets per month):

Before the deductible: Some MA-PD plans exempt Tier 1 generics from the Part D deductible entirely. If your plan applies the deductible to all tiers, you may pay the full negotiated price ($4 to $18) until the deductible is met.

Initial coverage phase: Copays of $0 to $15 apply for Tier 1 generics. Many plans from UnitedHealthcare (AARP Medicare Advantage), Humana, and Aetna advertise $0 Tier 1 copays as a plan benefit.

Coverage gap: Under the Inflation Reduction Act provisions effective 2025, the coverage gap (donut hole) has been effectively eliminated, with manufacturer discounts and plan subsidies reducing beneficiary cost-sharing to 25% of the negotiated price. For a $4 generic, that amounts to $1 per month.

Catastrophic phase: After reaching the $2,000 annual out-of-pocket cap, the beneficiary pays $0 for all Part D drugs for the remainder of the year.

A 2019 study published in Osteoporosis International found that out-of-pocket costs exceeding $30 per month were associated with a 32% increase in bisphosphonate discontinuation among Medicare beneficiaries. Generic alendronate's low price point removes cost as a barrier for most patients, which directly supports the long treatment durations (3 to 5 years minimum) that guidelines recommend.

Clinical Evidence Supporting Alendronate Coverage

Medicare Advantage plans cover alendronate because decades of randomized trial data support its efficacy in reducing fractures. Three statistics anchor the coverage rationale.

First, the landmark FIT trial (N=6,459) published in JAMA in 1998 showed that alendronate 5 to 10 mg daily reduced clinical vertebral fractures by 55% and hip fractures by 51% over a median 4.2 years compared with placebo in postmenopausal women with low bone density [1]. Second, a 2019 Cochrane systematic review (N=12,068 across 11 trials) confirmed that alendronate reduces vertebral fractures (RR 0.55, 95% CI 0.43 to 0.69) and non-vertebral fractures (RR 0.77, 95% CI 0.64 to 0.92) in postmenopausal women with osteoporosis [3]. Third, the FLEX extension trial demonstrated that women who took alendronate for 10 years had a 55% lower risk of clinical vertebral fractures compared with those who discontinued after 5 years, supporting the safety of extended use in high-risk patients [4].

The FDA approved alendronate (as Fosamax) in 1995 for treatment of osteoporosis in postmenopausal women, with subsequent approvals for prevention of postmenopausal osteoporosis, treatment of glucocorticoid-induced osteoporosis, treatment of osteoporosis in men, and treatment of Paget's disease of bone [5].

Dr. Ethel Siris, former director of the Toni Stabile Osteoporosis Center at Columbia University Medical Center, has noted: "Alendronate remains the most cost-effective first-line therapy for osteoporosis, with a safety and efficacy profile established over more than 25 years of clinical use."

The United States Preventive Services Task Force (USPSTF) recommends osteoporosis screening for women aged 65 and older and for younger postmenopausal women with risk factors. Pharmacotherapy with bisphosphonates is the standard follow-up for patients whose DXA results confirm osteoporosis (T-score of -2.5 or below) or osteopenia with elevated FRAX-calculated fracture risk.

Using Manufacturer Savings Cards with Medicare Advantage

Federal law prohibits Medicare beneficiaries from using manufacturer copay cards or savings coupons for drugs covered under Part D. This restriction applies to all Medicare Advantage prescription drug plans, regardless of the carrier. The OIG Anti-Kickback Statute guidance treats manufacturer copay assistance to federal healthcare program beneficiaries as a potential inducement.

There are two exceptions. Patient assistance programs (PAPs) offered by manufacturers may provide free medications to Medicare beneficiaries who meet income eligibility requirements. Merck, the manufacturer of brand Fosamax, has historically offered such programs through its Merck Helps program.

The second exception involves charitable foundations. Organizations like the Patient Access Network Foundation and NeedyMeds operate independently of manufacturers and may help Medicare beneficiaries with out-of-pocket costs for certain drug classes. However, given that generic alendronate costs $0 to $15 per month on most MA-PD plans, few beneficiaries will need financial assistance for this specific medication.

If cost is a concern, Medicare Extra Help (the Low-Income Subsidy, or LIS) reduces Part D premiums, deductibles, and copays for beneficiaries below 150% of the federal poverty level. Eligible beneficiaries pay no more than $4.50 for generic drugs in 2025. Applications are available through the Social Security Administration.

Important Safety Considerations for Alendronate

Medicare Advantage coverage of alendronate does not eliminate the need for proper patient selection and monitoring. The FDA label carries specific administration instructions: take alendronate first thing in the morning on an empty stomach with 6 to 8 ounces of plain water, remain fully upright (sitting or standing) for at least 30 minutes, and do not eat, drink, or take other medications during that 30-minute window [5].

Contraindications include esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, hypocalcemia, and hypersensitivity to any component of the formulation. Patients with chronic kidney disease (GFR <35 mL/min) should not receive alendronate due to insufficient renal clearance data.

Rare but serious adverse events include osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). A 2020 analysis in the Journal of Bone and Mineral Research estimated the incidence of AFF at 1.74 per 100,000 person-years during the first 5 years of bisphosphonate use, rising to 8.86 per 100,000 person-years after 8 or more years. These risks inform the AACE recommendation for a "drug holiday" reassessment after 5 years of oral bisphosphonate therapy in patients who are no longer at high fracture risk.

Medicare Advantage plans typically cover the DXA bone density scans used to monitor treatment response. CMS covers DXA screening every 24 months for qualified beneficiaries, or more frequently if medically necessary [6].